BioMed Research International

Research Article

Clinical Features of COVID-19 Patients with Different Outcomes in Wuhan: A Retrospective Observational Study

Table 3

Inflammatory responses and immunoreactions of COVID-19 patients on admission to the hospital.
Median (IQR)All ()Nonsurviving ()Surviving () value
Nonspecific inflammation index
 C-reactive protein, mg/L a36.6 (7.6, 85.4)86.1 (54, 168.9)11.6 (5, 41.4)<0.001
 >10, No. (%)186 (70.2%)104 (97.2%)82 (51.9%)<0.001
 High-sensitivity C-reactive protein, mg/L b5 (5, 5)5 (5, 5)5 (1.78, 5)<0.001
 >5, No. (%)40 (15.3%)22 (20.6%)18 (11.7%)0.050
 Procalcitonin, ng/mL c0.07 (0.04, 0.18)0.18 (0.1, 0.55)0.04 (0.03, 0.07)<0.001
Humoral immunity d
 Complement 3, g/L0.98 (0.83, 1.13)0.93 (0.79, 1.06)1.02 (0.85, 1.14)0.017
 Complement 4, g/L0.25 (0.19, 0.32)0.24 (0.17, 0.32)0.25 (0.2, 0.31)0.337
 Immunoglobulin A, g/L2.55 (1.9, 3.63)2.55 (1.9, 3.63)2.19 (1.72, 2.73)0.001
 Immunoglobulin E, IU/mL50.6 (18.3, 145.8)67.1 (31.4, 188)37 (18.3, 108)0.007
 Immunoglobulin G, g/L12.1 (10.43, 14.88)12.5 (10.7, 15.9)11.8 (10.1, 14.6)0.067
 Immunoglobulin M, g/L0.94 (0.68, 1.22)0.95 (0.7, 1.21)0.94 (0.67, 1.22)0.998
Cellular immunity e
 CD16+56, %13.58 (7.58, 22.56)19.2 (10.3, 29.3)11.6 (6.43, 17.03)<0.001
 CD16+56 counts, No./μL115 (69, 176)97 (41.5, 168.5)119.5 (77.5, 180.3)0.012
 CD19, %14.95 (11.46, 21.87)19.1 (11.7, 27.9)14.3 (11.4, 19.2)0.003
 CD19 counts, No./μL131 (82, 191)141 (87.5, 177)125.5 (78, 205.25)0.859
 CD3, %65.0 (53.3, 72.6)65.16 (51.78, 73.01)64.83 (53.65,72.44)0.914
 CD3 counts No./μL574 (294, 873)272 (185.5, 405)781 (582.3, 1023.8)<0.001
 CD4, %39.0 (31.4, 45.5)32.1 (26.7, 41.5)41.8 (36.3, 46.8)<0.001
 CD4 counts, No./μL357 (177, 547)168 (106.5, 269)486 (357.8, 651.5)<0.001
 CD8,%22.0 (14.9, 28.3)16.0 (10.9, 24.4)24.0 (18.8, 29.6)<0.001
 CD8 counts, No./μL182 (88, 319.5)73 (46.5, 131.5)263 (166.8, 396)<0.001
 CD4/CD81.78 (1.3, 2.52)1.85 (1.28, 3.11)1.74 (1.34, 2.29)0.187
The total number of patients with available data: a, ; b, ; c, ; d, ; e, .